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In this issue of Immunity, Zhang et al. (2009) propose that Treg cells, in order to efficiently control alloimmune
response, need to be educated first in the target tissue before entering the draining lymph node.Proper control of defined microenviron-
ments requires that regulatory elements
adapt but are also appropriately targeted
to the site of disease. One major arm of
the regulatory network is constituted by
regulatoryT (Treg) cells that restraina large
array of immune responses ranging from
self-reactive to pathogen-specific reac-
tions. Despite extensive studies on the
role of Treg cells in the control of periph-
eral homeostasis, the site(s) in which these
cells primarily act remains unclear. Treg
cells, consistent with their central role in
the preservation of tissue integrity, can
accumulate at sites of inflammation or
infection (Wei et al., 2006). However, in
most circumstances as in the context of
experimental colitis, Treg cells migrate
both to the draining lymphoid organ and
the inflamed site (Mottet et al., 2003). In
this issue of Immunity, Zhang et al. (2009)
showed that suppressive functions get
upregulated on the Treg cell when they
first traffic to the inflamed allograft and
that this education at the diseases site is
required for optimal control of responses
in both the lymph node and the tissue.
The question of whether Treg cells are
acting primarily in the draining lymph
node or the target tissue has been exam-
ined with the NOD mouse, a model for
autoimmune diabetes. However, conflict-
ing conclusions have been drawn in
different studies. In one set of studies,
transcriptional profiles of Treg cells iso-
lated from the pancreas were compared
to Treg cells from pancreatic draining
lymph nodes. Transcripts associated
with Treg cells effector functions, such as
IL-10, were found to be expressed at
higher amounts in Treg cells from the
pancreas, suggesting that the Treg cells
primarily act in the pancreatic lesion
(Chen et al., 2005). Another study showed322 Immunity 30, March 20, 2009 ª2009 Elsthat in the pancreatic lymph node, the
presence of Treg cells prevented stable
contacts between dendritic cells (DCs)
and effector T cells. This work suggests
that Treg cells are acting in the lymph
nodes by disrupting activation of effector
T cells by DCs, but does not exclude the
possibility of similar interactions occurring
in the tissue itself (Tang et al., 2006). Like-
wise, CD62L has been shown to be an
important marker identifying a subset of
Treg cells that can better suppress auto-
immunity in vivo (Tarbell et al., 2007).
Because CD62L expression is necessary
for T cells to traffic to the lymph nodes,
this data could be interpreted to mean
that Treg cells need to act in lymph nodes.
Evidence from a transplantation model
also suggested that Treg cells with
lymphoid tropism were better at control-
ling immune responses. In contrast, selec-
tive impairment of Treg cells to reach
tissues leads to spontaneous inflamma-
tory diseases (Sather et al., 2007). In
sum, these data, rather than antagonizing
one another, point to Treg cells having
effects both in the lymph nodes and in
the target tissue.
In the present study, Zhang et al. (2009)
confirm that both sites are indeed
controlled by Treg cells but also uncover
an intriguing scenario in which Treg cells
need to sequentially migrate to the graft
then to the lymph node to efficiently
control allogenic responses (Figure 1).
Using an islet allograft model, the authors
propose that Treg cells need to be
educated in the graft itself prior to their
drainage to the lymph node. Treg cells
migration to inflamed graft was dependent
on CCR2, CCR4, CCR5 and P- and
E-selectin, all necessary to ensure effi-
cient homing. This finding is consistent
with previous reports supporting a roleevier Inc.for these molecules in the homing of Treg
cells at inflamed site. Treg cell populations
in the blood are heterogeneous in terms of
their level of activation and/or chemokine
expression. Previous reports showed
that some subsets, and in particular Treg
cells expressing CD103, may preferen-
tially home to inflamed sites, supporting
the idea that Treg cells that have homed
in tissues enriched in TGF-b can patrol
the periphery (Huehn et al., 2004). How
the frequencies of preactivated Treg cells
or their antigen specificity is affected in
mice deficient in molecules shown to favor
tissue homing would be important to
consider in the interpretation of the
present data. Nevertheless, when directly
delivered or specifically targeted to the
graft, Treg cells became locally activated
and upregulated a large number of
effector molecules such as IL-10, TGF-b,
granzymes, and perforins. The nature of
the graft-specific signals received by
Treg cells remains unclear, but these
signals are likely to be factors associated
with tissue damage and inflammation.
ATP, for example, represents a constitu-
tive endogenous molecule that signals
tissue stress and injury. Treg cells express
high amounts of ectonucleotidases,
thereby allowing them to generate the
regulatory mediator adenosine and to
reduce the extracellular concentration of
the proinflammatory factor ATP (Deaglio
et al., 2007). In contrast, ATP or signaling
via ectonucleotidases may provide acti-
vating signal for Treg cells. In fact,
because of the fundamental role of Treg
cells in tissue homeostasis, most media-
tors of tissue damage are likely to directly
or indirectly contribute to Treg cells func-
tion. Another possibility is that the graft
environment and, in particular, activated
antigen-presenting cell may favor local
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PreviewsFigure 1. Sequential Recruitment of Treg Cells for Efficient Control of Inflammation
Treg cells migrate to the graft in response to inflammatory signals. In the graft, Treg cells become
activated. Activation may be a consequence of interaction via encounter with activated DCs, exposure
to damage-associated molecular pattern molecules, or inflammatory mediators. Activation leads to
upregulation of effector molecules on Treg cells and allow them to inhibit DC migration to the lymph
node (via IL-10 and TGF-b) and effector T cells’ entrance to the graft (via IL-10). Treg cells migrate to
the draining lymph node and further limit effector T cell accumulation in the lymph node as well as priming
of naive T cells.alloantigen-specific priming of Treg cells.
In the graft, Treg cells may also encounter
survival and activation factors such as IL-2
or TGF-b required to sustain their function
after their drainage to the lymph node.
Finally, exposure to the graft environment
may trigger the expression of homing
receptors on Treg cells necessary for their
efficient migration to the lymph node, in
this particular case CCR2, CCR5, and
CCR7. All together, these events may
arm and select Treg cells with antigen
specificities, survival factors, and effector
molecules, thus allowing them to expand
their regulatory function in the draining
lymph node. The functional consequence
of Treg cells entering both the graft and
the lymph node is to limit effector T cells
migration at both sites via their capacity
to release IL-10. Importantly, the authors
also proposed that Treg cells limited
donor-derived DC migration to the drain-
ing lymph node via their release of IL-10
and TGF-b, an event that would beexpected to control priming of effector
T cells. Previous reports demonstrate
that Treg cells can directly interact with
DCs in vivo. In vitro, Treg cells appear to
be more mobile than naive T cells,
outcompeting the latter in aggregating
around DCs (Onishi et al., 2008). After
forming aggregates, Treg cells specifically
downregulate the expression of CD80 and
CD86, but not CD40 or class II MHC, on
DCs in both a CTLA-4- and LFA-1-depen-
dent manner (Onishi et al., 2008). The
consequence of such interaction is
impaired capacity of DCs to establish
lasting interaction with effector T cells. In
the context of the present study, it will be
important to determine whether Treg cells
interact directly with graft-derived DCs to
limit their migration or function.
Interpretation of the present studies is
complicated by the fact that in vivo, distin-
guishing the role of chemokine receptors
on homing, local survival, and/or function
of Treg cells may be difficult. In addition,Immunityalthough some aspects of inflammation
seen in this model may inform other
diseases such as tumor, infection, or auto-
immune settings, an allograft may repre-
sent an unusual immune setting, and the
sequence of events described may be
specific to the experimental setting
described. Nevertheless, this study illus-
trates a fundamentally important point—
the requirement for Treg cells to target in
a coordinated fashion the diseased and
the priming site. Education of Treg cells
or amplification of their suppressive func-
tion at the inflamed site is likely to be
important in all settings. In fact, it would
be hard to conceive a model in which
regulation would not integrate a dialog
between the priming and effector site.
REFERENCES
Chen, Z., Herman, A.E., Matos, M., Mathis, D., and
Benoist, C. (2005). J. Exp. Med. 202, 1387–1397.
Deaglio, S., Dwyer, K.M., Gao, W., Friedman, D.,
Usheva, A., Erat, A., Chen, J.F., Enjyoji, K., Linden,
J., Oukka, M., et al. (2007). J. Exp. Med. 204, 1257–
1265.
Huehn,J., Siegmund,K., Lehmann,J.C., Siewert,C.,
Haubold, U., Feuerer, M., Debes, G.F., Lauber, J.,
Frey, O., Przybylski, G.K., et al. (2004). J. Exp.
Med. 199, 303–313.
Mottet, C., Uhlig, H.H., and Powrie, F. (2003).
J. Immunol. 170, 3939–3943.
Onishi, Y., Fehervari, Z., Yamaguchi, T., and
Sakaguchi, S. (2008). Proc. Natl. Acad. Sci. USA
105, 10113–10118.
Sather,B.D.,Treuting,P.,Perdue,N.,Miazgowicz,M.,
Fontenot, J.D., Rudensky, A.Y., and Campbell, D.J.
(2007). J. Exp. Med. 204, 1335–1347.
Tang, Q., Adams, J.Y., Tooley, A.J., Bi, M.,
Fife, B.T., Serra, P., Santamaria, P., Locksley,
R.M., Krummel, M.F., and Bluestone, J.A. (2006).
Nat. Immunol. 7, 83–92.
Tarbell, K.V., Petit, L., Zuo, X., Toy, P., Luo, X.,
Mqadmi, A., Yang, H., Suthanthiran, M., Mojsov,
S., and Steinman, R.M. (2007). J. Exp. Med. 204,
191–201.
Wei, S., Kryczek, I., and Zou, W. (2006). Blood 108,
426–431.
Zhang, N., Schro¨ppe, B., Lal, G., Jakubzick, C.,
Mao, X., Chen, D., Yin, N., Jessberger, R.,
Ochando, J.C., Ding, Y., and Bromberg, J.S.
(2009). Immunity 30, this issue, 458–469.30, March 20, 2009 ª2009 Elsevier Inc. 323
